Cullinan Therapeutics, Inc. (CGEM) stock
CGEMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$9.01−0.27 (-2.86%)
Close on Nov 18, 2026Market cap $579.84MP/E –Yield –
Cullinan Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Cullinan Therapeutics's free cash flow for the twelve months ending Dec 31, 2025 was -$175.80M. For fiscal 2025 it was -$175.80M. The highest annual figure on record is -$29.78M in fiscal 2020.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$175.80M | – |
| FY2024 | Dec 31, 2024 | -$145.30M | – |
| FY2023 | Dec 31, 2023 | -$134.48M | – |
| FY2022 | Dec 31, 2022 | -$127.80M | – |
| FY2021 | Dec 31, 2021 | -$43.43M | – |
| FY2020 | Dec 31, 2020 | -$29.78M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | -$38.12M | – |
| Q4 FY2024 | Dec 31, 2024 | -$36.63M | – |
| Q3 FY2024 | Sep 30, 2024 | -$34.14M | – |
| Q2 FY2024 | Jun 30, 2024 | -$36.29M | – |
| Q1 FY2024 | Mar 31, 2024 | -$38.25M | – |
| Q4 FY2023 | Dec 31, 2023 | -$18.13M | – |
| Q3 FY2023 | Sep 30, 2023 | -$34.14M | – |
| Q2 FY2023 | Jun 30, 2023 | -$31.06M | – |
| Q1 FY2023 | Mar 31, 2023 | -$51.16M | – |
| Q4 FY2022 | Dec 31, 2022 | -$25.87M | – |
| Q3 FY2022 | Sep 30, 2022 | -$54.60M | – |
| Q2 FY2022 | Jun 30, 2022 | -$25.42M | – |
| Q1 FY2022 | Mar 31, 2022 | -$21.91M | – |
| Q4 FY2021 | Dec 31, 2021 | -$15.17M | – |
| Q4 FY2020 | Dec 31, 2020 | -$9.44M | – |
| Q3 FY2020 | Sep 30, 2020 | -$9.08M | – |
| Q2 FY2020 | Jun 30, 2020 | -$6.25M | – |
| Q1 FY2020 | Mar 31, 2020 | -$5.02M | – |
See a number that looks wrong?